Evidence gap analysis
Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation
Recent news and posts
Details on renewed support via RIHN 2.0 for innovation in medical biology and anatomopathology procedures released in France
The General Directorate for Healthcare Services (DGOS) of the French Ministry of Labor, Health and Solidarity (Ministre du Travail, de la Santé et des Solidarités, MTSS) is working on the reform of the Repository of Innovative Services outside the Nomenclature of biology and anatomopathology (RIHN List) as part of the France 2030 plan.
On September 2, 2024, the MTSS published further details on the renewed support for innovation in medical biology and anatomopathology procedures via the RIHN 2.0. It includes the criteria for applying. To be eligible for RIHN 2.0 and funded under the framework, biology and anatomopathology procedures must:
- Prove their innovative nature;
- Deviate from article 2 of the decree of March 29, 2024, on the conditions for covering innovative procedures;
- Be described as a comprehensive act;
- If prescribed in a healthcare establishment, be financially covered under the MERRI G03 allocation on a transitional basis;
- Be subject to prospective and comparative data collection;
- Be exempt from the accreditation requirement by the French National Authority for Health (HAS).
More details can be found here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.